[ad_1]
Merck & Co Inc (MRK.N) and accomplice Ridgeback Biotherapeutics mentioned on Friday six lab research confirmed their experimental oral COVID-19 drug molnupiravir was lively towards the fast-spreading Omicron variant.
The info evaluated the antiviral exercise of molnupiravir and different COVID-19 antiviral brokers towards COVID-19 variants of concern. Molnupiravir is but to be studied towards Omicron in human research, the businesses mentioned.
Molnupiravir and a rival oral tablet from Pfizer Inc (PFE.N) had been approved in the US in December and are thought-about as necessary instruments towards Omicron.
Pfizer mentioned in December lab information recommended its drug Paxlovid retained its effectiveness towards Omicron.
Merck mentioned earlier this month its tablet has a mechanism that may work towards Omicron and another variant.
Molnupiravir has been approved to be used in additional than 10 international locations, together with the US, United Kingdom and Japan.- Reuters.
[ad_2]
Source link